The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
 
Sylvie Lorenzen
No Relationships to Disclose
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Roche; SERVIER
Research Funding - Merck Serono (Inst)
 
Claudia Pauligk
No Relationships to Disclose
 
Eray Goekkurt
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Roche; Sanofi; SERVIER
 
Thomas Jens Ettrich
Consulting or Advisory Role - Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; MSD; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi/Aventis
Research Funding - Baxalta/Shire
Travel, Accommodations, Expenses - Ipsen; Ipsen
 
Florian Lordick
Honoraria - AstraZeneca; BioNTech; Bristol-Myers Squibb; Elsevier; Infomedica; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Amgen; Astellas Pharma; Beigene; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; SERVIER; Zymeworks
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Michael Stahl
Honoraria - Amgen; Celgene; Lilly; Merck Serono; MSD; Pfizer; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD; Shire
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; MSD
 
Peter Reichardt
Honoraria - Amgen; Bayer; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Clinigen Group; Deciphera; Lilly; Novartis; Pfizer; PharmaMar; Roche
Research Funding - Novartis (Inst)
 
Martin Soekler
No Relationships to Disclose
 
Daniel Pink
Employment - Helios Kliniken
Consulting or Advisory Role - Clinigen Group (Inst); Lilly (Inst); Roche (Inst)
Research Funding - Clinigen Group (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
 
Stephan Probst
No Relationships to Disclose
 
Axel Hinke
Honoraria - Roche Pharma AG
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Lilly; MSD Oncology; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - Deutsche Forschungsgemeinschaft; Gemeinsamer Bundesausschuss
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - IKF Klinische Krebsforschung
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Sharp & Dohme; Nordic Bioscience; Roche
Speakers' Bureau - AIO gGmbH; Celgene; Forum für Medizinische Fortbildung; Lilly; MCI group; Nordic Bioscience
Research Funding - Celgene; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Lilly; Medac; Merck; Roche; Sanofi; Vifor Pharma